Not available
Quote | Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Last: | $21.32 |
---|---|
Change Percent: | -0.47% |
Open: | $21.55 |
Close: | $21.32 |
High: | $22.1 |
Low: | $20.945 |
Volume: | 544,046 |
Last Trade Date Time: | 05/31/2024 03:00:00 am |
News | Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...
2024-05-12 11:00:00 ET More on Acadia Pharma, BridgeBio Pharma, etc. ACADIA Pharmaceuticals Inc. (ACAD) Q1 2024 Earnings Call Transcript ACADIA Pharmaceuticals Inc. 2024 Q1 - Results - Earnings Call Presentation Rocket Pharmaceuticals: Cautiously Optimistic (Rating U...
Message Board Posts | Rocket Pharmaceuticals Inc. (NASDAQ:RCKT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RCKT News Article - Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Hea | whytestocks | investorshangout | 03/01/2023 9:05:48 PM |
whytestocks: $RCKT News Article - Rocket Pharmaceuticals Presents Positive Clinical Data from Fancon | whytestocks | investorshangout | 12/12/2022 4:10:48 PM |
whytestocks: $RCKT News Article - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EQ, RCKT, | whytestocks | investorshangout | 10/28/2022 7:50:57 PM |
whytestocks: $RCKT News Article - Rocket Pharmaceuticals Announces Presentations Highlighting Lentiv | whytestocks | investorshangout | 10/12/2022 3:45:49 PM |
whytestocks: $RCKT News Article - Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting | whytestocks | investorshangout | 10/10/2022 12:25:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Rocket Pharmaceuticals Inc. Company Name:
RCKT Stock Symbol:
NASDAQ Market:
Rocket Pharmaceuticals Inc. Website:
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Commission (EC), based on a positive opinion issued by the Committ...
Long-term KRESLADI TM follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in all nine patients with severe LAD-I Previously disclosed results from the global R...
Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio beginning with KRESLADI™ (marnetegragene autotemcel) for severe LAD-I; PDUFA date of Ju...